Edition:
United Kingdom

DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

40.42EUR
21 Feb 2018
Change (% chg)

-- (--)
Prev Close
€40.42
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
170,485
52-wk High
€86.64
52-wk Low
€32.88

Chart for

About

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to... (more)

Overall

Beta: 0.44
Market Cap(Mil.): €1,956.98
Shares Outstanding(Mil.): 24.10
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.60
EPS (TTM): -- -- --
ROI: -- 14.90 10.66
ROE: -- 16.41 14.30

BRIEF-DBV Technologies Cash And Cash Equivalents At Dec. 31 Down At 137.9 Million Euros

* ‍CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2017, WERE EUR 137.9 MILLION, VERSUS EUR 256.5 MILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

20 Feb 2018

BRIEF-Reg-Dbv Technologies Provides Update On Regulatory Progress For Viaskin Peanut

* REG-DBV TECHNOLOGIES PROVIDES UPDATE ON REGULATORY PROGRESS FOR VIASKIN PEANUT

14 Feb 2018

BRIEF-DBV Technologies ‍announces positive data from Phase IIb trial and long-term study of Viaskin Peanut​

* ‍ANNOUNCES PUBLICATION OF POSITIVE DATA FROM PHASE IIB TRIAL AND LONG-TERM STUDY OF VIASKIN PEANUT​

14 Nov 2017

BRIEF-DBV Technologies reports at Sept. 30 cash position of 170.5 million euros

* CASH POSITION AT SEPT. 30, 2017 EUR 170.5 MILLION VERSUS EUR 256.5 MILLION AT DEC. 31, 2016 ‍​ Source text: http://bit.ly/2htbI61 Further company coverage: (Gdynia Newsroom)

31 Oct 2017

BRIEF-DBV Technologies ‍cash position of 170.5 million euros as of September 30​

* ‍CASH AND CASH EQUIVALENTS AS OF SEPTEMBER 30, 2017, WERE EUR 170.5 MILLION, COMPARED TO EUR 256.5 MILLION AS OF DECEMBER 31, 2016 ​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

31 Oct 2017

BRIEF-DBV Technologies peanut allergy treatment fails to meet main goal in late-stage study

* DBV Technologies announces topline results of phase III clinical trial in peanut-allergic patients four to 11 years of age‍​

20 Oct 2017

DBV Technologies peanut allergy drug fails key study

DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study, sending its U.S.-listed shares sharply down.

20 Oct 2017

UPDATE 1-DBV Technologies peanut allergy drug fails key study

Oct 20 DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study, sending its U.S.-listed shares sharply down.

20 Oct 2017

DBV Technologies peanut allergy drug fails key study

Oct 20 Drug developer DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study.

20 Oct 2017

BRIEF-DBV Technologies completes blinded period in REALISE study of Viaskin Peanut

* REG-DBV TECHNOLOGIES ANNOUNCES COMPLETION OF BLINDED PERIOD IN REALISE STUDY OF VIASKIN PEANUT

12 Oct 2017

Earnings vs. Estimates